Litcius/Paper detail

Generation of an anti-idiotypic affibody-based masking domain for conditional activation of EGFR-targeting

Anna Mestre Borras, Charles Dahlsson Leitao, Stefan Ståhl, John Löfblom

2022New Biotechnology11 citationsDOIOpen Access PDF

Abstract

Conditional activation of engineered affinity proteins by proteolytic processing is an interesting approach for a wide range of applications. We have generated an anti-idiotypic masking domain with specificity for the binding surface of an EGFR-targeting affibody molecule using an in-house developed staphylococcal display method. The masking domain could specifically abrogate EGFR-binding on cancer cells when fused to the EGFR-targeting affibody molecule via a linker comprising a protease cleavage site. EGFR-binding was restored by proteolytic cleavage of the linker region resulting in release of the masking domain. A saturation mutagenesis study provided detailed information on the interaction between the EGFR-targeting affibody molecule and the masking domain. Introducing an anti-idiotypic masking affibody domain is a viable approach for blocking EGFR-binding and allows for conditional activation by proteolytic processing. The results warrant further studies evaluating the therapeutic and diagnostic applicability both in vitro and in vivo.

Topics & Concepts

LinkerChemistryCleavage (geology)Binding domainMutagenesisMasking (illustration)BiophysicsIn vitroCell biologyComputational biologyBinding siteBiochemistryBiologyComputer scienceMutationVisual artsArtOperating systemPaleontologyGeneFracture (geology)Monoclonal and Polyclonal Antibodies ResearchGlycosylation and Glycoproteins ResearchHER2/EGFR in Cancer Research
Generation of an anti-idiotypic affibody-based masking domain for conditional activation of EGFR-targeting | Litcius